Universal Vaccine on the horizon? Scripps Research Institute Unveils Promising New Approach
Table of Contents
Note: The image has no direct connection with the text / Image source: Motion Elements
The Scripps Research Institute (TSRI) in California presented findings at the ACS Spring 2025 meeting that could revolutionize vaccine development. Their research focuses on creating a “general vaccine” effective against a wide range of viral threats, including coronaviruses and potentially even cancer.
Many viruses,including coronaviruses,employ a clever tactic to evade the body’s defenses. They coat their surface with sugar molecules, effectively mimicking normal cells.This “sugar shield” makes it difficult for the immune system to recognize and attack the virus.
There is no recipe for the perfect vaccine. Despite the ever-increasing sophistication of vaccine technology,vaccine development frequently enough comes down to “suck it and see”. Many vaccines look promising in pre-clinical testing, only to fall over during the slow and expensive clinical trial process.
[1] World Economic forum
Professor Chihui Wong’s research team at TSRI is pioneering a new strategy.Rather of targeting the rapidly mutating regions of the virus, their vaccine focuses on the “stem area” of the spike protein. This stem is less prone to mutation and is coated with a molecular chain called “glycan,” wich shields it from immune detection.
The “Low-Sugar Vaccine” Concept
The TSRI team’s vaccine, dubbed a “low-sugar vaccine,” targets these glycan molecules, effectively dismantling the virus’s protective shield. Animal studies involving hamsters and rats have shown promising results, with the vaccine generating diverse antibodies effective against MERS-CoV (MERS virus) and various SARS-CoV variants.
‘Mortgage vaccine’ is a method of aiming for the effect as a ‘general vaccine’ by using the ‘stem part’ of the viral spike protein, which is unlikely to mutant.
The high mutation rate of viruses like SARS-CoV-2, especially in the receptor-binding domain (RBD) of the spike protein, necessitates frequent vaccine updates, similar to annual flu shots. The TSRI’s approach, by targeting a less mutable region, offers the potential for a single vaccine to provide long-lasting protection against a broad spectrum of coronaviruses.
the research extends beyond viral infections. Professor Wong’s team is also exploring the request of this “mortgage vaccine” technology in cancer treatment. Cancer cells often possess unique proteins or antigens.By targeting these with a similar approach, the researchers aim to stimulate an immune response against the cancer.
Targeting Cancer Cell Glycans
The “mortgage vaccine” strategy, with its focus on a small, less mutable area, could prove particularly effective against cancer cells that employ immune avoidance mechanisms. Recent publications from the team detail their research on glycan targets on cancer cells and enzymes involved in glycan synthesis.
The Road Ahead: Challenges and Opportunities
While these findings are encouraging, it’s important to remember that vaccine development is a complex and often unpredictable process. As the World Economic Forum notes, many promising vaccines fail during clinical trials [1]. However, the TSRI’s innovative approach offers a beacon of hope in the ongoing quest for universal vaccines and more effective cancer therapies.
The reason for the same variation as Omikron is that it causes mutation in the process of replicating the virus / Image source: Motion Elements
